Anupa Kudva

Statistics

Publications

Citations

1.1K

H-Index

Active since

2008

Affiliations

Instituto de Investigación Biomédica de Salamanca(Current)

Janssen (United States)

National and Kapodistrian University of Athens

Leicester Royal Infirmary

UCLouvain

Anupa Kudva is an author at Instituto de Investigación Biomédica de Salamanca specializing in multiple myeloma therapy, medicine, and multiple myeloma.

Publications per year

2008–2022

Publications

Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial

María‐Victoria Mateos, Michèle Cavo, Joan Bladé et al. · The Lancet · 2019 · 438 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Influenza A Inhibits Th17-Mediated Host Defense against Bacterial Pneumonia in Mice

Anupa Kudva, Erich V. Scheller, Keven M. Robinson et al. · The Journal of Immunology · 2010 · 341 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE

Jesús F. San Miguel, Hervé Avet‐Loiseau, Bruno Paiva et al. · Blood · 2021 · 141 citations · Full text

Medicine, Hematology, Oncology +14

Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE

María‐Victoria Mateos, Meletios Α. Dimopoulos, Michèle Cavo et al. · Clinical Lymphoma Myeloma & Leukemia · 2021 · 56 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Overall Survival in Alcyone

María‐Victoria Mateos, Michèle Cavo, Joan Bladé et al. · Blood · 2019 · 25 citations

Medicine, Hematology, Oncology +17

1–5 of 9